^{Photo: Bloomberg News}

Novo Nordisk is preparing for what could become the next major chapter in the rapidly expanding obesity treatment industry. After achieving strong momentum in the United States with its oral Wegovy treatment, the company is now shifting its focus toward global expansion, aiming to build demand far beyond its largest market.

The obesity drug race has largely revolved around the U.S. over recent years, where explosive demand for weight-loss therapies transformed the pharmaceutical industry and generated billions of dollars in sales. But as competition intensifies and global demand continues rising, international markets are increasingly becoming the next strategic battleground.

Novo believes the opportunity outside the United States could be enormous.

The Weight-Loss Drug Market Is Entering a Global Growth Phase

The obesity treatment market has experienced remarkable growth over the past few years.

Analysts estimate that the global obesity drug market could exceed $100 billion annually within the next decade, driven by increasing obesity rates, stronger patient awareness, and broader acceptance of GLP-1 therapies.

Until now, the United States has remained the center of that growth.

The U.S. currently generates more than half of sales for both Novo Nordisk and its biggest rival, Eli Lilly. However, both companies increasingly see future expansion coming from international markets.

Novo executives believe growing demand for obesity treatments, combined with improving healthcare access and digital platforms, creates significant room for growth outside North America.

The company is expected to begin initial international launches of the oral Wegovy treatment later this year, pending regulatory approvals.

Why Novo Is Betting Big on Oral Weight-Loss Treatment

Traditional injectable weight-loss treatments transformed the market, but oral medications may open the door to a much broader patient base.

Many patients prefer pills over injections because of convenience and ease of use.

Potential advantages include:

• Simpler treatment routines
• Reduced barriers for first-time users
• Improved patient comfort
• Easier long-term adoption
• Greater accessibility through digital healthcare channels

Novo's early launch performance in the United States has strengthened confidence surrounding its strategy.

The company reported that prescriptions for the Wegovy pill have already surpassed 2 million, significantly outperforming expectations in the early stages of commercialization.

The strong start has also strengthened awareness around the broader Wegovy brand.

Rather than replacing injectable treatments, the company views oral options as expanding the total market opportunity.

Telehealth Could Become a Major Growth Driver

One major factor shaping Novo's international strategy is telehealth.

Digital healthcare platforms have rapidly expanded across multiple countries, changing how patients access treatment and interact with healthcare providers.

Novo believes telehealth partnerships could accelerate obesity treatment adoption in several international markets.

Telehealth offers several potential advantages:

• Faster patient access
• Reduced wait times
• Improved treatment convenience
• Greater reach into underserved areas
• Easier ongoing monitoring and follow-up care

In some markets where obesity treatment adoption had previously been slow, digital healthcare channels have started changing patient behavior.

Healthcare analysts increasingly believe virtual care systems may play an important role in future obesity treatment growth.

Competition With Eli Lilly Is Entering a New Stage

Novo and Eli Lilly have become the dominant names in the modern obesity treatment market.

Their competition has intensified as both companies expand beyond injectable products and enter the oral treatment category.

However, the two approaches differ in important ways.

Novo's oral Wegovy treatment essentially extends an already established brand and uses a familiar active ingredient connected to its injectable portfolio.

Eli Lilly's Foundayo follows a different strategy, introducing a new molecule and a separate brand identity.

Early prescription data suggests Wegovy has built stronger initial momentum in comparable periods.

Lilly executives have acknowledged that building awareness around a new product may take more time.

Market analysts also believe the products could appeal to different groups of patients:

• Oral Wegovy may attract patients seeking efficacy closer to injectable therapies
• Foundayo may appeal to first-time users entering GLP-1 treatment categories

Rather than simply competing for existing users, both products may help enlarge the overall obesity treatment market.

Novo Faces New Challenges Despite Strong Demand

While Novo has maintained an early lead in several areas, the company also faces growing pressures.

The company recently indicated expectations for weaker growth compared with previous years, citing factors such as:

• Lower pricing pressure in the U.S. market
• Growing generic competition
• Expansion of lower-cost alternatives
• Competitive pressure from rival treatments
• Increasing international market complexity

Generic competition is expected to affect regions including:

• India
• Brazil
• China
• Canada

As more competitors enter the obesity treatment space, maintaining pricing power may become increasingly difficult.

Europe Could Become an Early Focus Area

Industry analysts believe some of Novo's earliest international launches could happen in major European markets.

Countries frequently highlighted include:

• United Kingdom
• Germany
• Denmark

These markets offer several advantages:

• Large patient populations
• High healthcare spending
• Established healthcare systems
• Growing acceptance of obesity treatment

However, rollout strategies will likely depend on demand forecasts, physician education, reimbursement structures, and supply capabilities.

Novo appears to be prioritizing markets where infrastructure can support rapid adoption.

Out-of-Pocket Spending Is Becoming a Major Trend

One notable shift in the obesity treatment industry is how patients are paying for care.

Even in countries with highly developed public healthcare systems, many patients continue paying directly for obesity treatments.

This trend suggests patient demand may be stronger than many initially expected.

For years, obesity treatment struggled with reimbursement challenges because many healthcare systems viewed weight management differently from other chronic conditions.

That perception has gradually changed as obesity becomes increasingly recognized as a serious medical issue associated with diabetes, cardiovascular disease, and broader health risks.

The willingness of patients to pay directly for treatment has become one of the strongest growth drivers for the industry.

The Next Phase of the Weight-Loss Race May Happen Outside America

Novo Nordisk's strategy signals a broader shift happening throughout the pharmaceutical sector.

The first phase of the obesity revolution focused heavily on creating highly effective treatments and establishing market leadership in the United States.

The next phase may center on international expansion.

As healthcare systems evolve, digital treatment channels expand, and patient demand grows globally, the competition between Novo Nordisk and Eli Lilly may increasingly move beyond American borders.

For Novo, the challenge now is not simply maintaining leadership in the world's largest obesity market.

The bigger opportunity may be turning a U.S. success story into a global healthcare business.